Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Medical Innovation: FDA OKs Pill with Sensor that Digitally Tracks If Patients Have Ingested Medication

Washington, DC, November 28, 2017 — The U.S. Food and Drug Administration (FDA) on November 13 approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken.

The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults.

The system works by sending a message from the pill’s sensor to a wearable patch. The patch transmits the information to a mobile application so that patients can track the ingestion of the medication on their smart phone. Continue reading

Rutgers New Jersey Medical School Research: Controlling Diabetes with Your Phone Might be Possible Someday

Newark, NJ, November 27, 2017 — Think about this.  You have diabetes, are trying to control your insulin levels and instead of taking a pill or giving yourself an injection, you click an app on your phone that tells your pancreas to bring blood sugar levels back to normal.

Sound improbable?  Not according to Luis Ulloa, an immunologist at Rutgers New Jersey Medical School in a paper published in Trends in Molecular Medicine.

“Our bodies are a lot like rooms in a house,” says Ulloa. “In order to see when you enter a darkened room, you need electricity to turn on the lights. Our body is like that room and has an electrical network that can be used to manipulate and help control how it works.” Continue reading

Opinion: BIO CEO Jim Greenwood on ‘Don’t Let Fear Trump Science – Vaccinate Your Child’

Jim Greenwood

Washington, DC, November 26, 2017Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood wrote the following op-ed that was published in The Philadelphia Inquirer on August 23:

The nice lady had sugar cubes. My classmates and I lined up, single file, at Richboro Elementary School more than half a century ago, waiting for our taste. For a kid, it was a serendipitous moment — our parents were actually ordering us to consume sweets to keep us healthy.

These were no ordinary sugar cubes, though. We were in line to take the new oral polio vaccine. Continue reading

Rutgers Names David Kimball as VP for Innovation and Research Commercialization of Office of Research and Economic Development

Dr. David Kimball

New Brunswick, NJ, November 25, 2017 — Rutgers University on October 23 announced the appointment of David Kimball, Ph.D., as vice president for innovation and research commercialization of the Office of Research and Economic Development (ORED).

Most recently, Dr. Kimball led translational science and research commercialization as associate vice president in ORED.

“I am delighted to announce David’s promotion to Vice President of Innovation and Research Commercialization,” said Christopher J. Molloy, Ph.D., R.Ph., Senior Vice President for Research and Economic Development at Rutgers University. Continue reading

NJIT’s $21 Million State-of-the-Art Life Sciences and Engineering Center Opens for Innovation

NJIT President Joel Bloom (second from left) and Gov. Chris Christie

Newark, NJ, November 24, 2017 — An array of innovation-focused New Jerseyans – scientists, student researchers, alumni, company executives and elected officials — gathered on campus on September 21 to hail the much-anticipated opening of NJIT’s new Life Sciences and Engineering Center, a $21 million state-of-the-art research facility focused on the future of health care.

Governor Chris Christie helped cut the ribbon on the New Jersey Institute of Technology’s $19 million Life Sciences and Engineering Center, funded by $13.5 million in state Higher Education Capital Facilities grants, including Building Our Future Bond Act (GO Bond) funds. Continue reading

NIH Awards to Test Ways to Store, Access, Share and Compute on Biomedical Data in the Cloud

Bethesda, MD, November 23, 2017 — The National Institutes of Health (NIH) on November 6 announced that 12 awards totaling $9 million in Fiscal Year 2017 will launch an NIH Data Commons Pilot Phase.

A data commons is a shared virtual space where scientists can work with the digital objects of biomedical research, such as data and analytical tools.  The NIH Data Commons will be implemented in a four-year pilot phase to explore the feasibility and best practices for making digital objects available through collaborative platforms.

This will be done on public clouds, which are virtual spaces where service providers make resources, such as applications and storage, available over the internet. Continue reading

Rutgers-Camden’s New Nursing and Science Building’s Labs Offer Greater Learning and Research Opportunities

Camden, NJ, November 22, 2017 — “It’s been a long time coming,” says Danny Bubb, professor and chair of the physics and chemistry departments, as he gives a tour of the cutting-edge science labs in the new Rutgers University–Camden Nursing and Science Building (NSB).

Jeanne Leong reports that in the NSB, located at Fifth and Federal Sts. in Camden, the three new state-of-the-art physics labs provide students and faculty with access to resources including a high-powered microscope, laser systems, and a vibration-free work table only a few other colleges and universities even have.

“These new labs allow us to be very innovative with how we deliver our curriculum to engage students,” says Bubb. Continue reading

Hill Fight Erupts Over GOP’s Proposed Roll-Back of Tax Credit for ‘Orphan’ Disease Drugs

Washington, DC, November 21, 2017 — Peter Sullivan reports in The Hill that Republicans are seeking to roll back a tax credit for drugs that treat rare diseases, alarming patient groups who fear the move would slow the development of new treatments.

The so-called orphan drug tax credit would be repealed in the tax-reform bill that passed the House last week. Patient groups are lobbying to preserve the credit, as are some drug companies.

The credit, first enacted in 1983, is intended to spur the development treatments for rare, or “orphan,” diseases that affect fewer than 200,000 people. Continue reading

Seven Princeton University Researchers Receive NIH BRAIN Initiative Awards

Princeton, NJ, November 21, 2017 — Liz Fuller-Wright reports that  Princeton University projects are among the 121 selected by the National Institutes of Health (NIH) to receive an overall $219 million in funds related to the federal Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative.

Launched in 2013 by the Obama Administration, the BRAIN Initiative is a large-scale effort to push the boundaries of neuroscience research and equip scientists with insights necessary for treating a wide variety of brain disorders such as Alzheimer’s disease, schizophrenia, autism, epilepsy and traumatic brain injury. Continue reading

FDA Announces Comprehensive Regenerative Medicine Policy Framework

Washington, DC, November 20, 2017 — The U.S. Food and Drug Administration (FDA) on November 16 announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies.

The framework – outlined in a suite of four guidance documents – builds upon the FDA’s existing risk-based regulatory approach to more clearly describe what products are regulated as drugs, devices, and/or biological products.

Further, two of the guidance documents propose an efficient, science-based process for helping to ensure the safety and effectiveness of these therapies, while supporting development in this area. Continue reading